✦ LIBER ✦

ChemInform Abstract: 1-Phenyl-5-pyrazolyl Ureas: Potent and Selective p38 Kinase Inhibitors.

✍ Scribed by Jacques Dumas; et al. et al.

Publisher: John Wiley and Sons
Year: 2000
Weight: 27 KB
Volume: 31
Category: Article
ISSN: 0931-7597
DOI: 10.1002/chin.200049228

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

ChemInform Abstract: 5-Amino-pyrazoles a

ChemInform Abstract: 5-Amino-pyrazoles as Potent and Selective p38α Inhibitors.

✍ Jagabandhu Das; et al. et al. 📂 Article 📅 2011 🏛 John Wiley and Sons ⚖ 22 KB 👁 1 views

ChemInform Abstract: Potent Inhibitors o

ChemInform Abstract: Potent Inhibitors of the MAP Kinase p38.

✍ James R. Henry; Kenneth C. Rupert; John H. Dodd; Ignatius J. Turchi; Scott A. Wa 📂 Article 📅 2010 🏛 John Wiley and Sons ⚖ 29 KB 👁 1 views

ChemInform Abstract: Discovery of PH-797

ChemInform Abstract: Discovery of PH-797804, a Highly Selective and Potent Inhibitor of p38 MAP Kinase.

✍ Shaun R. Selness; et al. et al. 📂 Article 📅 2011 🏛 John Wiley and Sons ⚖ 21 KB 👁 1 views

## Abstract The synthesis and SAR studies of a novel N‐aryl pyridinone class of p38 kinase inhibitors are described.

ChemInform Abstract: p38 Kinase Inhibito

ChemInform Abstract: p38 Kinase Inhibitors for the Treatment of Arthritis and Osteoporosis: Thienyl, Furyl, and Pyrrolyl Ureas.

✍ William J. Scott; et al. et al. 📂 Article 📅 2001 🏛 John Wiley and Sons ⚖ 26 KB 👁 2 views

ChemInform Abstract: Design and Synthesi

ChemInform Abstract: Design and Synthesis of Potent, Selective, and Orally Bioavailable Tetrasubstituted Imidazole Inhibitors of p38 Mitogen-Activated Protein Kinase.

✍ Nigel J. Liverton; et al. et al. 📂 Article 📅 2010 🏛 John Wiley and Sons ⚖ 32 KB 👁 2 views

ChemInform Abstract: Substituted N-Aryl-

ChemInform Abstract: Substituted N-Aryl-6-pyrimidinones: A New Class of Potent, Selective, and Orally Active p38 MAP Kinase Inhibitors.

✍ Balekudru Devadas; et al. et al. 📂 Article 📅 2011 🏛 John Wiley and Sons ⚖ 22 KB 👁 1 views

## Abstract A series of highly potent and selective p38 MAP kinase inhibitors is developed originating from a substituted N‐aryl‐6‐pyrimidinone scaffold.